LeBaron Matthew J, Rasoulpour Reza J, Gollapudi B Bhaskar, Sura Radhakrishna, Kan H Lynn, Schisler Melissa R, Pottenger Lynn H, Papineni Sabitha, Eisenbrandt David L
The Dow Chemical Company, Toxicology and Environmental Research and Consulting, Midland, Michigan 48674
The Dow Chemical Company, Toxicology and Environmental Research and Consulting, Midland, Michigan 48674.
Toxicol Sci. 2014 Nov;142(1):74-92. doi: 10.1093/toxsci/kfu155. Epub 2014 Aug 4.
The key events responsible for mouse liver tumors induced by a pesticide (viz., pronamide) were investigated in a series of studies employing molecular, biochemical, cellular, and apical endpoints. Based on these studies, it was demonstrated that the liver tumors were mediated by a mode of action (MoA) involving nuclear receptors (NRs) through the following key events: (1) CAR and PPAR-α receptor activation, (2) increased hepatocellular proliferation, eventually leading to (3) hepatocellular tumors. Specifically, gene expression analysis indicated robust, simultaneous coactivation of the CAR and PPAR-α NRs, as indicated by the induction of hepatic Cyp2b10 and Cyp4a10 transcripts, in response to dietary administration of pronamide to mice. The presence of hepatocellular hypertrophy and peroxisome proliferation was indicative of the activation of these two NRs at carcinogenic dose levels. Demonstrated induction of Cyp2b10 gene and protein, however, was not accompanied by enhancement of the corresponding enzyme activity (7-pentoxyresorufin-O-dealkylase (PROD)), suggesting that pronamide administration resulted in mechanism-based (suicide) inhibition of the enzyme in vivo. This was confirmed with an in vitro assay for suicide inhibition, where pronamide and/or its metabolites irreversibly inhibited Cyp2b10-mediated PROD activity. Analysis of hepatocellular proliferation via BrdU incorporation indicated a clear dose- and duration-related induction of S-phase DNA synthesis only in animals treated at and above the carcinogenic dose level. The available MoA data were evaluated for weight-of-evidence based upon the Bradford Hill criteria, followed by a human relevance framework. The conclusion from this evaluation is that pronamide-induced mouse liver tumors occur via an NR-mediated MoA involving CAR and PPAR-α activation and this MoA is not relevant to humans based on qualitative/quantitative differences between mice and humans.
在一系列采用分子、生化、细胞和顶端终点指标的研究中,对一种农药(即拿草特)诱发小鼠肝脏肿瘤的关键事件进行了调查。基于这些研究,结果表明肝脏肿瘤是通过一种涉及核受体(NRs)的作用模式(MoA)介导的,具体通过以下关键事件:(1)CAR和PPAR-α受体激活,(2)肝细胞增殖增加,最终导致(3)肝细胞肿瘤。具体而言,基因表达分析表明,给小鼠喂食拿草特后,肝脏Cyp2b10和Cyp4a10转录本的诱导表明CAR和PPAR-α核受体同时被强烈激活。在致癌剂量水平下,肝细胞肥大和过氧化物酶体增殖的存在表明这两种核受体被激活。然而,Cyp2b10基因和蛋白的诱导并未伴随着相应酶活性(7-戊氧基试卤灵-O-脱烷基酶(PROD))的增强,这表明拿草特给药导致该酶在体内发生基于机制的(自杀性)抑制。这一点通过自杀性抑制的体外试验得到了证实,在该试验中,拿草特和/或其代谢产物不可逆地抑制了Cyp2b10介导的PROD活性。通过BrdU掺入分析肝细胞增殖表明,只有在致癌剂量水平及以上处理的动物中,才出现与剂量和持续时间相关的S期DNA合成明显诱导。根据Bradford Hill标准,随后采用人类相关性框架,对现有的作用模式数据进行了证据权重评估。该评估的结论是,拿草特诱导的小鼠肝脏肿瘤是通过涉及CAR和PPAR-α激活的NR介导的作用模式发生的,基于小鼠和人类之间的定性/定量差异,这种作用模式与人类无关。